Neoantigen vaccines have demonstrated a favorable safety profile and the ability to elicit robust CD4⁺ and CD8⁺ T cell responses across various cancer types and disease stages.
First-pass extracted concept
neoantigen vaccines
Candidate: concept label1 source documents3 linked claims
Live refresh every 5sNext refresh in 5s
Evidence Snippets
Supporting Sources
Linked Claims
Peptide-based vaccines have evolved through use of long synthetic peptides and identification of tumor-specific neoantigens.
Optimal efficacy of neoantigen vaccines depends on careful antigen selection favoring clonal driver mutations and timely administration in early-stage or minimal residual disease settings.
Neoantigen vaccines have shown favorable safety profiles and robust CD4-positive and CD8-positive T cell responses across multiple cancer types and disease stages.